Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday.
禮來（紐交所：LLY）、諾和諾德（紐交所：NVO）、viking therapeutics（納斯達克：VKTX）和結構療法公司（納斯達克：GPCR）的股票週三交投走低。
What happened? Earlier on Wednesday, Roche Holdings AG (OTC:RHHBY) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity.
發生了什麼？週三早些時候，羅氏控股AG（場外交易：RHHBY）宣佈了Ct-996治療2型糖尿病和肥胖症一項正在進行中的多部分第一期臨床試驗的兩個分支的頭部結果。
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
數據顯示，Ct-996在沒有2型糖尿病的肥胖病人中治療4周後，平均體重損失較安慰劑組減少了6.1%，屬於臨床意義上的。
This data is better compared to existing competitors.
與現有競爭對手相比，這些數據更好。
Also Read: EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO.
還閱讀：獨家：Tema etf CEO預測GLP-1減重藥市場可能成爲萬億市場。
In March, Viking Therapeutics released results from the company's Phase 1 multiple ascending dose trial of an oral tablet formulation of VK2735 in development for metabolic disorders such as obesity.
3月份，viking therapeutics公佈了該公司VK2735口服片劑的一項一期多劑量試驗的結果，該試驗正在開發用於代謝性疾病如肥胖症。
Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline of up to 5.3%, and relative to placebo, ranging up to 3.3%.
接受VK2735的隊列顯示出基線平均體重的劑量依賴性降低，最高可達5.3％，且相對於安慰劑範圍高達3.3％。
In a study published on the JAMA Internal Medicine website, Eli Lilly's Mounjaro users experienced a mean loss in body weight of 5.9% at three months, compared to 3.6% for Novo Nordisk's Ozempic users.
在JAMA內科網站上發表的一項研究中，禮來的Mounjaro用戶在三個月內的平均體重減輕了5.9％，而諾和諾德的Ozempic用戶減輕了3.6％。
At six months, the mean loss was 10.1% for Mounjaro users versus 5.8% for Ozempic users. At 12 months, the mean body weight loss for Mounjaro users was 15.3% and 8.3% for Ozempic users.
到了六個月時，Mounjaro用戶的平均減肥量爲10.1％，而Ozempic用戶爲5.8％。到12個月時，Mounjaro用戶的平均體重減輕量爲15.3％，而Ozempic用戶爲8.3％。
In June, Structure Therapeutics Inc. (NASDAQ:GPCR) unveiled 12-week topline obesity data from its Phase 2a study of GSBR-1290, demonstrating a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks.
6月份，GPCR公佈了GSBR-1290臨床研究的12周頭部肥胖數據，顯示12周內體重平均減輕了6.2％，存在臨床意義和統計學意義上顯著的安慰劑調整。
At Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss, and 33% achieved ≥ 10% weight loss, compared to 0% for placebo.
在第12周，GSBR-1290組中有67%的參與者達到≥6%體重減輕目標，33%的人達到了≥10%的體重減輕目標，而安慰劑組爲0%。
Price Action: At last check Wednesday, LLY stock was down 3.00% at $913.37, NVO shares were down 4.15% at $135.02, GPCR stock was down 16.01% at $37.50, and VKTX shares were down 11.10% at $50.70.
股票走勢：截至週三最後一次檢查，LLY股票下跌3.00％至913.37美元，NVO股票下跌4.15％至135.02美元，GPCR股票下跌16.01％至37.50美元，VKTX股票下跌11.10％至50.70美元。
- Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient.
- 一項研究顯示，僅有25%的患者在使用諾和諾德的Wegovy或Ozempic 2年後仍堅持使用；公司稱數據不足。
Photo by Vidmir Rais via Pixabay
來自Pixabay的Vidmir Rais攝影作品